Literature DB >> 34054018

Patient and Relative Experiences and Decision-making About Genetic Testing and Counseling for Familial ALS and FTD: A Systematic Scoping Review.

Ashley Crook1,2,3, Chris Jacobs1, Toby Newton-John1, Ebony Richardson1, Alison McEwen1.   

Abstract

Genetic testing and counseling is an emerging part of care for patients with amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) and their families. This scoping review aimed to map patients' and relatives' experiences of genetic testing and counseling for familial ALS and FTD and the factors influencing their decision to proceed with testing or counseling. Informed by the Joanna Briggs Institute methodology, 5 databases were systematically searched. Thirty studies from 39 references were included. A descriptive numerical summary analysis and narrative synthesis was conducted. Mostly positive diagnostic testing experiences were reported, but issues arose due to progressive disease and discordant results. Predictive testing impacted at-risk relatives, regardless of the result received, and psychosocial sequelae ranged from relief to guilt, worry or contemplating suicide. Four reproductive testing experiences were reported. Personal, familial and practical factors, and the lived experience of disease, informed decision-making. Greater uncertainty and complexity may be faced in familial ALS/FTD than in other late-onset neurodegenerative diseases due to clinical and genetic heterogeneity, and testing limitations. Genetic counseling models of care should consider this difference to ensure that individuals with, or at risk of, ALS/FTD are effectively managed. Implications for research and practice are discussed.
Copyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.

Entities:  

Mesh:

Year:  2021        PMID: 34054018     DOI: 10.1097/WAD.0000000000000458

Source DB:  PubMed          Journal:  Alzheimer Dis Assoc Disord        ISSN: 0893-0341            Impact factor:   2.703


  4 in total

1.  Genetic counselling and testing for neurodegenerative disorders using a proposed standard of practice for ALS/MND: diagnostic testing comes first.

Authors:  Ashley Crook; Alison McEwen
Journal:  Eur J Hum Genet       Date:  2022-01-05       Impact factor: 4.246

2.  Predictive genetic testing for Motor neuron disease: time for a guideline?

Authors:  Alisdair McNeill; Maria-Del-Mar Amador; Hilary Bekker; Angus Clarke; Ashley Crook; Cathy Cummings; Alison McEwen; Christopher McDermott; Oliver Quarrell; Alessandra Renieri; Jennifer Roggenbuck; Kristiana Salmon; Alexander Volk; Jochen Weishaupt
Journal:  Eur J Hum Genet       Date:  2022-04-05       Impact factor: 5.351

3.  Psychological Impact of Predictive Genetic Testing for Inherited Alzheimer Disease and Frontotemporal Dementia: The IT-DIAfN Protocol.

Authors:  Samantha Galluzzi; Anna Mega; Giuseppe Di Fede; Cristina Muscio; Sara Fascendini; Luisa Benussi; Fabrizio Tagliavini; Giovanni B Frisoni; Emilio Di Maria
Journal:  Alzheimer Dis Assoc Disord       Date:  2022-03-16       Impact factor: 2.357

4.  Exploring experiences and needs of spousal carers of people with behavioural variant frontotemporal dementia (bvFTD) including those with familial FTD (fFTD): a qualitative study.

Authors:  Sara Tookey; Caroline V Greaves; Jonathan D Rohrer; Roopal Desai; Joshua Stott
Journal:  BMC Geriatr       Date:  2022-03-07       Impact factor: 3.921

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.